Chugai Pharmaceutical Statistics
Total Valuation
Chugai Pharmaceutical has a market cap or net worth of 79.25 billion. The enterprise value is 73.70 billion.
| Market Cap | 79.25B |
| Enterprise Value | 73.70B |
Important Dates
The last earnings date was Friday, October 25, 2024.
| Earnings Date | Oct 25, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
| Shares Outstanding | n/a |
| Shares Change (YoY) | +0.01% |
| Shares Change (QoQ) | +0.01% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 639.51M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | n/a |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 19.64, with an EV/FCF ratio of 30.08.
| EV / Earnings | 27.29 |
| EV / Sales | 9.83 |
| EV / EBITDA | 19.64 |
| EV / EBIT | 20.79 |
| EV / FCF | 30.08 |
Financial Position
The company has a current ratio of 5.89
| Current Ratio | 5.89 |
| Quick Ratio | 4.67 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | 67,522.21 |
Financial Efficiency
Return on equity (ROE) is 23.20% and return on invested capital (ROIC) is 20.24%.
| Return on Equity (ROE) | 23.20% |
| Return on Assets (ROA) | 17.37% |
| Return on Capital (ROIC) | 20.24% |
| Revenue Per Employee | 1.05M |
| Profits Per Employee | 355,215 |
| Employee Count | 7,604 |
| Asset Turnover | 0.59 |
| Inventory Turnover | 1.22 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +60.94% in the last 52 weeks. The beta is 0.53, so Chugai Pharmaceutical's price volatility has been lower than the market average.
| Beta (5Y) | 0.53 |
| 52-Week Price Change | +60.94% |
| 50-Day Moving Average | 23.96 |
| 200-Day Moving Average | 19.71 |
| Relative Strength Index (RSI) | 50.77 |
| Average Volume (20 Days) | 284,154 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Chugai Pharmaceutical had revenue of 7.97 billion and earned 2.70 billion in profits. Earnings per share was 1.64.
| Revenue | 7.97B |
| Gross Profit | 5.62B |
| Operating Income | 3.77B |
| Pretax Income | 3.77B |
| Net Income | 2.70B |
| EBITDA | 3.96B |
| EBIT | 3.77B |
| Earnings Per Share (EPS) | 1.64 |
Balance Sheet
| Cash & Cash Equivalents | 5.90B |
| Total Debt | n/a |
| Net Cash | 5.90B |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 12.57B |
| Book Value Per Share | 7.64 |
| Working Capital | 8.58B |
Cash Flow
In the last 12 months, operating cash flow was 2.93 billion and capital expenditures -477.49 million, giving a free cash flow of 2.45 billion.
| Operating Cash Flow | 2.93B |
| Capital Expenditures | -477.49M |
| Free Cash Flow | 2.45B |
| FCF Per Share | n/a |
Margins
Gross margin is 70.48%, with operating and profit margins of 47.29% and 33.87%.
| Gross Margin | 70.48% |
| Operating Margin | 47.29% |
| Pretax Margin | 47.29% |
| Profit Margin | 33.87% |
| EBITDA Margin | 49.64% |
| EBIT Margin | 47.29% |
| FCF Margin | 30.73% |
Dividends & Yields
Chugai Pharmaceutical does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 34.45% |
| Buyback Yield | -0.01% |
| Shareholder Yield | -0.01% |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Stock Splits
The last stock split was on July 6, 2020. It was a forward split with a ratio of 12.
| Last Split Date | Jul 6, 2020 |
| Split Type | Forward |
| Split Ratio | 12 |
Scores
Chugai Pharmaceutical has an Altman Z-Score of 23.76.
| Altman Z-Score | 23.76 |
| Piotroski F-Score | n/a |